Study guide
10.1 DSCSA Track-and-Trace Requirements: Transaction Information & Statements
NABP MPJE Multistate Pharmacy Jurisprudence Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pharmacist Licensure & Reciprocity
1.1 Initial Licensure Requirements & Examinations 1.2 License Renewal, Continuing Education (CE) & Status 1.3 Reciprocity, License Transfer & Multistate Licensure 1.4 Disciplinary Actions, Board Hearings, Sanctions & Reinstatement
2 Chapter 2: Pharmacy Personnel Roles & Supervision Ratios
2.1 Pharmacy Interns: Scope of Practice, Supervision & Preceptor Rules 2.2 Pharmacy Technicians: Registration, Certification & Permitted Duties 2.3 Technician-to-Pharmacist Ratios & Delegated Tasks 2.4 Non-Pharmacist Personnel & Automated Dispensing Technology Roles
3 Chapter 3: Prescriptive Authority & Practitioner Categories
3.1 Physicians, Dentists, Veterinarians & Podiatrists: Prescribing Scope 3.2 Mid-Level Practitioners: APNs, PAs, Optometrists & Independent Authority 3.3 Out-of-State, Foreign & Deceased Practitioner Prescriptions 3.4 Self-Prescribing & Prescribing for Family Members
4 Chapter 4: Patient Counseling & Drug Utilization Review (OBRA '90)
4.1 OBRA '90 Mandates & Prospective Drug Utilization Review (DUR) 4.2 Patient Counseling Requirements, Offer-to-Counsel & Documentation 4.3 Patient Profile Requirements & Retrospective DUR
5 Chapter 5: Advanced Pharmacist Practice & Collaborative Agreements
5.1 Collaborative Practice Agreements (CPAs) & Protocol-Based Care 5.2 Pharmacist Immunization Authority & Vaccine Administration Protocols 5.3 Medication Therapy Management (MTM) & Point-of-Care Testing (POCT) 5.4 Hormonal Contraceptive, Naloxone & Post-Exposure Prophylaxis (PEP/PrEP) Prescribing
6 Chapter 6: Federal Controlled Substances Act (CSA) & Scheduling
6.1 Controlled Substance Schedules (CI through CV) & Classification Criteria 6.2 DEA Registration: Types, Forms (224, 225, 363) & Renewal Cycles 6.3 Scheduled Listed Chemical Products (SLCPs) & Combat Methamphetamine Epidemic Act (CMEA)
7 Chapter 7: Controlled Substance Prescriptions & Legitimate Purpose
7.1 Corresponding Responsibility & Red Flags for Improper Prescribing 7.2 Required Components of Controlled Substance Prescriptions 7.3 Electronic Prescriptions for Controlled Substances (EPCS) & Security Requirements 7.4 Emergency Schedule II Prescriptions & Partial Filling Rules (CARA Act)
8 Chapter 8: Controlled Substance Ordering, Inventory & Recordkeeping
8.1 Ordering Schedule II Substances: CSOS & DEA Form 222 Execution 8.2 Controlled Substance Inventory Requirements (Initial, Biennial, Count Exactness) 8.3 Theft, Significant Loss (DEA Form 106) & Disposal/Destruction (DEA Form 41) 8.4 Prescription Transfers & Prescription Drug Monitoring Programs (PDMPs)
9 Chapter 9: Federal Pure Food, Drug & Cosmetic Act (FD&C Act) & Drug Safety
9.1 Adulteration vs. Misbranding: Statutory Definitions & Legal Violations 9.2 Prescription Labeling Requirements, Expiration Dates & Side Effect Statements 9.3 Poison Prevention Packaging Act (PPPA) & Child-Resistant Container Exemptions 9.4 Drug Recalls (Class I, II, III) & Market Withdrawals 9.5 Drug Product Selection, Generic Substitution & DAW Codes 9.6 Returning & Reusing Dispensed Drugs: Restocking, Redispensing & Repository Programs
10 Chapter 10: Drug Supply Chain Security Act (DSCSA) & Commercial Distribution
10.1 DSCSA Track-and-Trace Requirements: Transaction Information & Statements 10.2 Suspect & Illegitimate Product Verification, Quarantine & Notification 10.3 Prescription Drug Marketing Act (PDMA): Samples, Reimportation & Wholesale Distribution
11 Chapter 11: Compounding Standards: USP <795>, <797> & <800>
11.1 Section 503A vs. 503B Compounding Facilities (DQSA Architecture) 11.2 Non-Sterile Compounding (USP <795>) & Beyond-Use Dating (BUD) 11.3 Sterile Compounding (USP <797>): Air Quality, Cleanrooms & BUD 11.4 Hazardous Drug Handling (USP <800>): Engineering Controls & Personal Protective Equipment
12 Chapter 12: Pharmacy Operational Security, Records & Telepharmacy
12.1 Physical Pharmacy Security, Alarm Systems & Keyholder Rules 12.2 Mandatory Pharmacy Records Retention & Audit Inspection Readiness 12.3 Central Fill, Automated Dispensing Systems (ADS) & Telepharmacy Operations 12.4 HIPAA Privacy Rule, Patient Records & Breach Notification Protocols
10.1 DSCSA Track-and-Trace Requirements: Transaction Information & Statements
Key Takeaways Explain This Topic AI
The Drug Supply Chain Security Act (DSCSA) of 2013 (Title II of DQSA) mandates an interoperable, electronic, package-level system to trace human prescription drugs across the U.S. supply chain.
Trading partners must exchange product tracing documentation, Transaction Information (TI) and the Transaction Statement (TS), for every transfer of ownership; FDA says the requirement to provide and receive Transaction History (TH) effectively ended on November 27, 2023.
All trading partners—including manufacturers, wholesale distributors, repackagers, and dispensers (pharmacies)—must retain product tracing records for a minimum of six (6) years from the date of the transaction.
Individual prescription packages must feature a 2D Data Matrix product identifier containing the National Drug Code (NDC), unique serial number, lot number, and expiration date.
Dispensing under a prescription, intracompany distribution, distribution for emergency medical reasons (an ordinary drug shortage does not count), and minimal quantities sent by a retail pharmacy to a practitioner for office use are excluded from the DSCSA definition of a transaction.
Last updated: November 2026
10.1 DSCSA Track-and-Trace Requirements: Transaction Information & Statements
MPJE Core Concept: Title II of the Drug Quality and Security Act (DQSA) of 2013, known as the Drug Supply Chain Security Act (DSCSA) , establishes a national, electronic, interoperable system to trace human prescription drugs at the package level as they move through commercial distribution. Pharmacists must understand trading partner qualifications, mandatory product tracing documentation (transaction information and the transaction statement), record retention rules, and exempt transactions.
Legislative Overview and Objectives
Prior to the enactment of the DSCSA in November 2013, state laws governed drug pedigree requirements, resulting in a fragmented patchwork of state regulations and paper-based tracing. The DSCSA created a uniform federal framework to protect consumers from drugs that are counterfeit, stolen, contaminated, adulterated, or otherwise dangerous.
The law establishes a ten-year phased implementation model culminating in full, electronic, interoperable package-level product tracing among all commercial trading partners.
Primary Goals of the DSCSA
Standardized Tracing: Implement electronic product tracing across manufacturers, repackagers, wholesale distributors, and dispensers (3PLs are trading partners but are not subject to section 582 product tracing).
Product Identification: Require unique 2D Data Matrix barcodes containing standardized numeric identifiers (SNIs) on all individual prescription packages.
Verification & Quarantine: Mandate protocols to quarantine, investigate, and notify regulatory authorities regarding suspect or illegitimate products.
Trading Partner Verification: Restrict all commercial drug transactions exclusively to Authorized Trading Partners (ATPs) .
Authorized Trading Partners (ATPs)
Under the DSCSA, a dispenser (pharmacy) may only accept ownership of prescription drugs from an Authorized Trading Partner . Operating with an unlicensed or unregistered entity constitutes a federal violation.
Trading Partner Type Licensure / Registration Requirement
Manufacturer Registered with the FDA under Section 510 of the FD&C Act.
Repackager Registered with the FDA under Section 510 of the FD&C Act.
Wholesale Distributor Licensed by the state from which the drug is shipped and the state into which it is received; reported to the FDA database.
Third-Party Logistics Provider (3PL) Licensed by the state or FDA under 21 U.S.C. 360eee-3.
Dispenser (Pharmacy) Licensed as a pharmacy by the state board of pharmacy in the state of operation.
Key Exam Tip: A pharmacy must verify that its wholesale distributors and manufacturers are validly licensed ATPs prior to purchasing prescription drug inventory.
Product Identifier & Standardization
The DSCSA mandates that manufacturers and repackagers affix a 2D Data Matrix barcode containing four critical data elements (the Product Identifier ) on each individual package and homogenous case of prescription drug:
National Drug Code (NDC): Standard 10- or 11-digit identifier.
Unique Serial Number: An alphanumeric string up to 20 characters assigned to that specific individual package.
Lot Number: Manufacturer batch/lot code.
Expiration Date: Format set by federal standards.
These elements must appear in both machine-readable format (2D Data Matrix barcode) and human-readable format on the package label.
Required Product Tracing Documentation
When ownership of a prescription drug is transferred within the supply chain, the seller must provide the buyer with transaction information and a transaction statement. Older materials teach three documents, the 3 T's , but FDA says that beginning November 27, 2023, section 582(k)(1) of the FD&C Act effectively ended the requirement for trading partners to provide and receive transaction history:
1. Transaction Information (TI)
Transaction Information includes the explicit physical and commercial details of the drug product involved in the transfer:
- Name of the drug product
- Strength and dosage form of the product
- National Drug Code (NDC)
- Container size and number of containers
- Lot number of the product
- Date of the transaction
- Date of shipment (if different from transaction date)
- Business name and address of the entity transferring ownership (seller)
- Business name and address of the entity receiving ownership (buyer)
- 2. Transaction History (TH) — no longer required
Transaction History was a paper or electronic statement accounting for the cumulative sequence of prior transactions for the product, back to the original manufacturer. It detailed each prior transfer of ownership, including dates and business names/addresses of all intermediate trading partners.
(Note: The requirement to provide and receive transaction history ended November 27, 2023, under section 582(k)(1) of the FD&C Act.)
3. Transaction Statement (TS)
Transaction Statement is a formal statement (electronic or written) submitted by the entity transferring ownership, attesting that the entity:
Is an Authorized Trading Partner under the DSCSA.
Received the product from an Authorized Trading Partner.
Received Transaction Information and Transaction Statement from the seller (if applicable).
Did not knowingly ship a suspect or illegitimate product.
Had systems and processes in place to comply with DSCSA verification requirements.
Did not knowingly alter the product history or falsify information.
6-Year Record Retention Requirement
All trading partners in the supply chain—including community, health-system, and specialty pharmacies—must retain their TI and TS documentation for a minimum of six (6) years from the date of the transaction. +-----------------------------------------------------------------------------+
- | DSCSA 6-YEAR RECORD RETENTION RULE |
- | |
- | All Transaction Information (TI) and Transaction Statements (TS) |
- | MUST be retained for at least 6 YEARS |
- | from the date of transaction. |
- | |
- | * Must be retrievable upon request during FDA or State Board inspections. |
- | * Electronic storage is standard and acceptable if securely backed up. |
- +-----------------------------------------------------------------------------+
- Exempt Transactions from Product Tracing
Not every transfer of a prescription drug requires the exchange of product tracing documentation. Congress established specific statutory exemptions tailored to routine patient care and emergency situations.
Transaction Type TI/TS Required? Statutory Rationale / Exam Context
Patient Prescription Dispensing NO (Exempt) Dispensing a prescription drug directly to a patient or end-user pursuant to a lawful prescription order.
Intracompany Transfers NO (Exempt) Transferring inventory between two pharmacies under common ownership or control (e.g., store #101 to store #102).
Emergency Medical Distribution NO (Exempt) Distributing product for emergency medical reasons, such as a declared public health emergency; a drug shortage not caused by a public health emergency does not count.
Minimal Quantity Transfers NO (Exempt) Retail pharmacy transferring minimal quantities of a drug to a practitioner for office use (subject to state pharmacy act limits).
Dispenser-to-Dispenser Sale for a Specific Patient Need NO (Exempt) A dispenser selling product to another dispenser to fill a specific patient need does not have to provide TI/TS (FD&C Act section 582(d)(1)(A)(ii)).
Commercial Wholesale Sales YES (Required) Routine wholesale purchase of inventory by a pharmacy from a distributor or manufacturer.
Comparative Summary: Tracing Documents at a Glance
Document Core Definition Key Data Included
Transaction Information (TI) Specific product & shipment details Drug name, strength, dosage form, NDC, lot, container size, count, shipment date, buyer/seller addresses
Transaction History (TH) Cumulative history of prior transfers; no longer required since November 27, 2023 Chain of ownership from original manufacturer through all intermediate distributors
Transaction Statement (TS) Legal compliance attestation Affidavit confirming ATP status, legitimate sourcing, non-falsification, and verification compliance